Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Most Read

  1. FDA accelerated review denial is a blow to Spectrum’s poziotinib
  2. New drugs and therapeutic options help the immune system fight cancer
  3. Roche’s Tecentriq threatens BMS’ Opdivo in small cell lung cancer market
  4. The challenges of using stem cells in neurology
  5. Another BACE inhibitor fails in phase III trials

Latest Content

Immunoassay Technology

Gyrolab users regard this system as a must-have technology for accelerating biopharmaceutical development and production.

Quick and Flexible Elemental Screening with Omnian

Omnian was developed for Malvern Panalytical's high-end x-ray fluorescence (XRD) spectrometer and is also available for the Epsilon 4 energy dispersive x-ray fluorescence (EDXRF) benchtop systems. This powerful combination brings together the strengths of Omnian with the ease-of-use of Epsilon 4.

April’s top news stories

Chinese clinical-stage biopharmaceutical company I-Mab Biopharma and German biotech company MorphoSys have begun the first dosed Phase III clinical study to assess investigational human CD38 antibody TJ202/MOR202 in combination with lenalidomide in patients suffering from relapsed or refractory multiple myeloma; and A small clinical trial by researchers at the University of Edinburgh in the UK has showed that cilostazol and isosorbide mononitrate could prevent recurrence of stroke and vascular dementia. Drugdevelopment-technology.com wraps up the key headlines from April 2019.

Eligen® Technology Mechanism of Action

Emisphere's Eligen® Technology binds a delivery agent with a therapeutic compound without alternation. This process occurs when both agent and compound are in close proximity.

March’s top news stories

Aldeyra Therapeutics reported positive data from the Phase III ALLEVIATE trial that evaluated the efficacy and safety of 0.25% and 0.5% concentrations of reproxalap topical ophthalmic solution to treat patients with allergic conjunctivitis.

Stem Cells Sourced from Healthy and Diseased Donors

Caltag Medsystems specialises in procuring haematopoietic cells collected from healthy and diseased donors. Its suppliers are able to isolate and purify haematopoietic cells from a variety of tissues, including peripheral blood, mobilised peripheral blood, bone marrow and cord blood.

Latest News

Read our magazine

Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

Send me notifications of new editions:

Close
Close
Close

Go Top